UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 13, 2011
Streamline Health Solutions, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
0-28132
|
|
31-1455414 |
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.) |
|
|
|
10200 Alliance Road, Suite 200,
Cincinnati, OH
|
|
45242-4716 |
|
|
|
(Address of principal executive offices)
|
|
(Zip Code) |
Registrants telephone number, including area code: (513) 794-7100
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
Item 2.03 CREATION OF A DIRECT FINANCIAL OBLIGATION
On April 13, 2011, Streamline Health, Inc. (the Borrower), a wholly owned subsidiary of
Streamline Health Solutions, Inc. (the Registrant), entered into a Second Amended and Restated
Revolving Note with Fifth Third Bank, Cincinnati, OH. The terms of the loan remain the same as set
forth in the amended and restated revolving note entered into on October 21, 2009, except as
follows: (i) the maximum principal amount that can be borrowed will increase to $3,000,000.00 as of
October 1, 2011 from the current maximum amount of $2,750,000.00; and (ii) the maturity date of the
loan has been extended to October 1, 2013 from October 1, 2011.
The loan continues to be guaranteed by the Registrant. In connection with entering into the Second
Amended and Restated Revolving Note, on April 13, 2011, the Registrant entered into Amendment No. 1
to the Amended and Restated Continuing Guaranty Agreement dated as of October 21, 2009. The terms
of the continuing guarantee agreement remain the same, except as follows: (i) the minimum fixed
charge ratio covenant has been revised to require that as of the end of the fiscal quarter ending
October 31, 2011 and at the end of each fiscal quarter thereafter, the Registrants minimum
trailing twelve months fixed charge ratio must be less than 1.25 to 1.0 rather than the current
required ratio of 1.10 to 1.0; and (ii) a covenant has been added to require that the Registrant
shall not permit its capitalized software development costs to exceed the Registrants EBITDA for
the nine month period ending October 31, 2011 and thereafter for the twelve month period ending on
each of January 31, April 30, July 31 and October 31 thereafter.
The loan continues to be secured by a first lien on all of the assets of the Registrant and the
Borrower pursuant to security agreements previously entered into by each of the Registrant and the
Borrower. Prior to entering into the revised loan documents, the Registrant and the Borrower were
in full compliance with the terms of its credit facility with Fifth Third Bank and there were no
defaults.
The complete terms of the revised loan documents are set forth in the Second Amended and Restated
Revolving Note, and Amendment No. 1 to the Amended and Restated Continuing Guarantee Agreement,
entered into by each of the Registrant and the Borrower and attached as Exhibits 10.1 and 10.2,
respectively. All defined terms used in this Form 8-K and not defined herein, have the meanings
set forth in the Second Amended and Restated Revolving Note and Amendment No. 1 to the Amended and
Restated Continuing Guarantee Agreement, as applicable.
Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
2